Copyright: ©Author(s) 2026.
World J Transplant. Jun 18, 2026; 16(2): 120865
Published online Jun 18, 2026. doi: 10.5500/wjt.v16.i2.120865
Published online Jun 18, 2026. doi: 10.5500/wjt.v16.i2.120865
Table 2 Available data on strategies targeting hepatic ischemia-reperfusion injury
| Strategy/drug | Animal evidence | Human evidence | Reported effect |
| Melatonin | Extensive | Limited | Positive |
| N-acetylcysteine | Extensive | Moderate | Mixed |
| Nobel gases | Limited | Limited | Insufficient |
| Caspase inhibitors | Extensive | Limited | Positive |
| P-selectin antagonists | Moderate | Limited | Mixed |
| Prostaglandins | Extensive | Moderate | Positive |
| Remifentanil | Moderate | Limited | Positive |
| Noble gases | Limited | Limited | insufficient |
| Akt activators | Moderate | None | Positive |
| PPARγ agonists | Moderate | None | Positive |
| miRNA based therapies | Moderate | None | Positive |
| Stem cell therapies | Extensive | Limited | Positive |
| Ischemic preconditioning | Expensive | Moderate | Positive |
| Ischemic postconditioning | Moderate | Limited | Mixed |
| Machine perfusion techniques | Extensive | Extensive | Positive |
- Citation: Mouratidou C, Pavlidis ET, Katsanos G, Kofinas A, Marneri AG, Stavrati KE, Tsoulfas G, Pavlidis TE. Preconditioning with sufentanil confers protective effects in transplantation by attenuating hepatic ischemia-reperfusion injury. World J Transplant 2026; 16(2): 120865
- URL: https://www.wjgnet.com/2220-3230/full/v16/i2/120865.htm
- DOI: https://dx.doi.org/10.5500/wjt.v16.i2.120865